Avecho completes treatment for Phase III interim analysis
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited has announced the completion of the treatment phase for its Phase III insomnia trial, which involved the last patient required for the interim analysis. The interim analysis is a significant milestone for Avecho, as it will inform the final trial size and support ongoing licensing discussions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Expiry of Listed Options
- March 2026 Quarterly Activities Report & Appendix 4C
- Avecho completes recruitment for Phase III interim analysis
- Annual Report 31 December 2025
- December 2025 Quarterly Activities Report & Appendix 4C
Later from Avecho Biotechnology
- Receipt of Research & Development Tax Incentive
- Positive interim results from Phase III insomnia program
- Positive interim analysis advances Avecho Phase III insomnia program
- June 2026 Quarterly Activities Report & Appendix 4C
- Avecho enters final stage of Phase III insomnia trial
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology